Damage-associated molecular pattern

Calluna Pharma Launches and Announces EUR 75 Million Series A Financing to Develop Novel Therapies for Inflammatory and Fibrotic Diseases

Retrieved on: 
Tuesday, January 23, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Phospholipid, Pharma, Patient, Therapy, Damage-associated molecular pattern, DAMP, Idiopathic pulmonary fibrosis, Complementarity, Rheumatoid arthritis, Asthma, Scleroderma, Immune system, MBA, Chronic kidney disease, Disease, EUR, Doctor of Philosophy, General partnership, Pharmaceutical industry

Calluna has raised EUR 75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53, and Investinor.

Key Points: 
  • Calluna has raised EUR 75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53, and Investinor.
  • Calluna is developing novel therapies that harness the transformative potential of the body's immune system.
  • As a result, Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases.
  • The Company is raising further financing to develop its pipeline to multiple key clinical milestones over the next 2.5 years.

Promontory Therapeutics to Present Research on PT-112 in Advanced Non-Small Cell Lung Cancer at the ESMO Immuno-Oncology Congress 2022

Retrieved on: 
Wednesday, November 30, 2022
NCI, Immunogenic cell death, NSCLC, Cancer, Merck Group, Safety, Large-cell lung carcinoma, Therapy, Patient, Damage-associated molecular pattern, Tumor microenvironment, Oncology, Abstract (summary), Orphan drug, Trial of the century, ICD, ESMO, ASH, César Award for Best Poster, CET, B cell, Research, Congress, Development of the human body, Merck Serono, European Society for Medical Oncology, Avelumab, Pharmaceutical industry

Abstracts will be published online on the ESMO website at 12:05 a.m. CET on Thursday, Dec. 1, 2022.

Key Points: 
  • Abstracts will be published online on the ESMO website at 12:05 a.m. CET on Thursday, Dec. 1, 2022.
  • Abstracts will also be published online in the ESMO-IO Congress 2022 Abstract Book, a supplement to the official ESMO journal, Immuno-Oncology and Technology (IOTECH).
  • PT-112 represents a highly potent inducer of this immunological form of cancer cell death.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.

Promontory Therapeutics Appoints Stan Musial as Chief Financial Officer

Retrieved on: 
Monday, November 28, 2022
NCI, CFO, Immunogenic cell death, History, Executive, Temple University, Darmstadt, Merck Group, Therapy, Biotechnology, MBA, Damage-associated molecular pattern, BS, Certified Public Accountant, IPO, Tumor microenvironment, Orphan drug, Trial of the century, Assertio Therapeutics, CPA, B cell, PD, KPMG, Research, State university system, Merck Serono, Promontory, Avelumab, Management, Pharmaceutical industry

NEW YORK, Nov. 28, 2022 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today announced the appointment of Stanley J. Musial, CPA, MBA, as Chief Financial Officer. Musial brings over 25 years of financial, strategic and managerial experience with public and private biotechnology companies, with a demonstrated history in capital raising, IPO execution, mergers and acquisitions, corporate development and investor relations.

Key Points: 
  • NEW YORK, Nov. 28, 2022 /PRNewswire/ -- Promontory Therapeutics Inc. , a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, todayannounced the appointment ofStanley J. Musial, CPA, MBA, as Chief Financial Officer.
  • "We welcome Stan to the Promontory team at an exciting and pivotal time in our corporate development.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.
  • To learn more about Promontory Therapeutics, visit the company's website here .

Lanier Biotherapeutics Announces Issuance of U.S. Patent for IL-25 Binding Molecules

Retrieved on: 
Monday, November 14, 2022
Type 2, Degenerative disease, Cytokine, Retina, Patent, Cancer, Allergen, Damage-associated molecular pattern, LNR, Virus, Inflammation, Asthma, Viral load, Neutralizing antibody, Allergy, Dermatitis, Vaccine, Lanier, Dermatology

This patent covers our novel approach to treating Type 2 inflammatory disease and is a key addition to our growing intellectual property estate, said Daniel White, President and CEO of Lanier.

Key Points: 
  • This patent covers our novel approach to treating Type 2 inflammatory disease and is a key addition to our growing intellectual property estate, said Daniel White, President and CEO of Lanier.
  • Because many currently available treatments for Type 2 inflammatory disease target particular downstream cytokines, they miss the opportunity to target other mediators.
  • IL-25 binding molecules, including LNR 125, target upstream cytokines called the Alarmins, the very first inflammatory trigger, which enables an effect on all downstream cytokines simultaneously.
  • Lanier Biotherapeutics was founded to develop first-in-class biologics portfolio for specialty disease, with the ultimate goal of improving the way we survive, age, and live.

SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company

Retrieved on: 
Friday, November 4, 2022
Technology, Company, SM03, Pemphigus, Research, Central China, Therapy, Growth, Asthma, The Company, Non-Hodgkin lymphoma, State Council, NHL, Damage-associated molecular pattern, Lupus, Twelfth, Sino Biopharmaceutical Limited, SLE, Barakat Pharmaceutical Group, RA, Rheumatoid arthritis, The Group, Thirteenth, WANG, CD22, Autoimmune disease, B-cell lymphoma, Mab, Degenerative disease, Pharmaceutical industry, Group

Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company.

Key Points: 
  • Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company.
  • Mr. Shanchun WANG has rich experience and practical achievements in corporate strategic management, organizational management, innovation research and development and product commercialization.
  • Dr. Shui On LEUNG said that: "It is a great pleasure to have Mr. Shanchun WANG joining the Company.
  • Pursuant to the subscription agreement, Mr. Shanchun WANG conditionally agreed to subscribe for and the Company conditionally agreed to allot and issue 14,340,000 subscription shares.

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Retrieved on: 
Wednesday, October 26, 2022
ICD, SEC, Company, Squamous cell carcinoma, Security (finance), U.S. Securities and Exchange Commission, Bevacizumab, Damage-associated molecular pattern, NASDAQ, CRC, Private Securities Litigation Reform Act, DNA, Cancer, Lung cancer, Goal, Forward-looking statement, DNA repair, Terminology, Pemetrexed, Large-cell lung carcinoma, Immunotherapy, Docetaxel, Protide, Pembrolizumab, Patient, PD-1, Immunogenic cell death, GLOBE, FOLFIRI, Thymidylate synthase, NCNA, Adenocarcinoma, Vaccine, Pharmaceutical industry, NSCLC

BARCELONA, Spain, Oct. 26, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced non-clinical data from two poster presentations at the 34th EORTC-NCI-AACR Annual Meeting being held from October 26 to 28, 2022.

Key Points: 
  • BARCELONA, Spain, Oct. 26, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced non-clinical data from two poster presentations at the 34th EORTC-NCI-AACR Annual Meeting being held from October 26 to 28, 2022.
  • NUC-3373 generated high intracellular levels of the anti-cancer metabolite FUDR-MP, resulting in TS inhibition, and the DNA-targeting metabolite, FUDR-TP.
  • These data highlight that NUC-3373 may be an effective treatment for non-small cell lung cancer (NSCLC) regardless of histological subtype and basal TS expression.
  • NUC-3373 causes NSCLC cells to release damage associated molecular patterns (DAMPs), molecular signals that activate immune cells leading to immunogenic cell death (ICD).

Promontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR Symposium

Retrieved on: 
Wednesday, October 26, 2022
Independent Greeks, ASH, Merck Serono, Biochemistry, Congress, American Association for Cancer Research, Therapy, Patient, B cell, European Organisation for Research and Treatment of Cancer, Research, Promontory, Orphan drug, University, ICD, Treatment, Tumor microenvironment, Trial of the century, AACR, NSCLC, Doctor of Philosophy, National Cancer Institute, Department, Mitochondrion, American Association, Development of the human body, CEST, EORTC, Patent, Prostate cancer, Safety, Merck Group, National, ESMO, Immunogenic cell death, Reactive oxygen species, Damage-associated molecular pattern, César Award for Best Poster, NCI, Large-cell lung carcinoma, Pharmaceutical industry, Platinum, Vaccine, Medical imaging, Cancer

"Ongoing studies into PT-112's ability to induce immunogenic cell death and cancer cell organelle stresses have been encouraging and support our elucidation of the drivers of PT-112's validated immunogenic cancer cell death," said Promontory co-founder and Chief Operating Officer Matthew Price.

Key Points: 
  • "Ongoing studies into PT-112's ability to induce immunogenic cell death and cancer cell organelle stresses have been encouraging and support our elucidation of the drivers of PT-112's validated immunogenic cancer cell death," said Promontory co-founder and Chief Operating Officer Matthew Price.
  • The non-clinical study of PT-112 was designed to continue the characterization of PT-112's effects on mitochondria in a panel of human prostate cancer cell lines.
  • Key study findings included:
    Human prostate cancer cell lines exhibited differential metabolic features when compared to the healthy prostate cell line RWPE-1.
  • After brief durations of PT-112 exposure, electron microscopy revealed noteworthy changes in prostate cancer cell mitochondrial structure in response to PT-112.

Promontory Therapeutics Receives U.S. Patent for Therapeutic Applications of PT-112 as an Immuno-Modulatory Agent

Retrieved on: 
Thursday, October 20, 2022
Merck Serono, ASH, Congress, Therapy, ENA, Patient, B cell, Drug resistance, Research, Promontory, Orphan drug, ICD, Tumor microenvironment, Trial of the century, AACR, NSCLC, Development of the human body, National Cancer Institute, United States Patent and Trademark Office, Patent, Immunotherapy, Safety, Merck Group, National, ESMO, Immunogenic cell death, Damage-associated molecular pattern, César Award for Best Poster, NCI, Large-cell lung carcinoma, Pharmaceutical industry, Cancer

"This U.S. patent issuance underscores our approach to oncologic small molecule immunotherapies along with our robust clinical pipeline assessing PT-112 alone and in immunotherapy combination."

Key Points: 
  • "This U.S. patent issuance underscores our approach to oncologic small molecule immunotherapies along with our robust clinical pipeline assessing PT-112 alone and in immunotherapy combination."
  • The patent, titled "Phosphaplatin Compounds as Immuno-Modulatory Agents and Therapeutic Uses Thereof," was issued on Sept. 13, 2022 as U.S. Patent No.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.
  • To learn more about Promontory Therapeutics, visit the company's website here .

Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy

Retrieved on: 
Tuesday, October 18, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Immunoglobulin G, Lymph, Therapy, Neoplasm, MTD, FIH, HKEX, Antibody, Patient, OX40, Research, Restitutio ad integrum, Cancer, Technology, Multinational corporation, Tumor microenvironment, Lung cancer, Prostate, Pharmacokinetics, Adult, Safety, Immunogenic cell death, Damage-associated molecular pattern, Fine chemical, Pharmaceutical industry, Vaccine

Under the terms of the agreement, Syncromune will acquire exclusive worldwide rights for development and commercialization of the intratumoral combination therapy containing Eucures YH002, and multiple other active ingredients as part of the Syncrovax therapy.

Key Points: 
  • Under the terms of the agreement, Syncromune will acquire exclusive worldwide rights for development and commercialization of the intratumoral combination therapy containing Eucures YH002, and multiple other active ingredients as part of the Syncrovax therapy.
  • Eucure will be responsible for drug manufacturing and supply, and Syncromune will be responsible for clinical development and commercialization.
  • The Syncrovax platform is a next-generation personalized cancer therapy being developed to optimize intratumoral immunotherapy for the treatment of metastatic solid tumor cancers.
  • As a wholly owned subsidiary of Biocytogen, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications.

Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax™ Immunotherapy Platform

Retrieved on: 
Tuesday, October 18, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Immunoglobulin G, Lymph, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Therapy, Achievement, Neoplasm, MTD, FIH, HKEX, Antibody, Patient, OX40, Research, Restitutio ad integrum, Security (finance), Cancer, Securities Act of 1933, Technology, Goal, Tumor microenvironment, Multinational corporation, Lung cancer, Company, Prostate, Industry, Pharmacokinetics, Adult, Immunotherapy, Safety, Phrase, Immunogenic cell death, Damage-associated molecular pattern, Fine chemical, Pharmaceutical industry, Vaccine

Eucure will be responsible for drug manufacturing and supply, and Syncromune will be responsible for clinical development and commercialization.

Key Points: 
  • Eucure will be responsible for drug manufacturing and supply, and Syncromune will be responsible for clinical development and commercialization.
  • The Syncrovax platform is a next-generation personalized cancer therapy being developed to optimize intratumoral immunotherapy for the treatment of metastatic solid tumor cancers.
  • "We are excited to enter into an exclusive licensing agreement with Eucure/Biocytogen," said Eamonn Hobbs, President and Chief Executive Officer of Syncromune.
  • This license agreement is an important step in the development of our proprietary Syncrovax platform and further supports Syncromunes strategy to maximize our platform to build a sustainable cancer therapeutics company."